MétaCan
← tous les travaux

RETRACTED: Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes

2022· article· en· 18 citations· W4224081928 sur OpenAlex· 10.1111/jcmm.17286

Pourquoi ce travail est-il dans la base ?

Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.

Affiliation canadienneUne personne signataire a déclaré un établissement canadien. C'est la seule voie dont dispose la base habituelle.

Dossier post-publication

OpenAlex signale ce travail comme rétracté, mais aucune notice correspondante de Retraction Watch ne figure dans cette base.

Résumé

Arsenic trioxide (ATO) and statins have been demonstrated to have anti-neoplastic properties; however, the data regarding their combination therapy is limited. Thus, we aimed to study the effects of ATO, Simvastatin and their combination in proliferation, apoptosis and pathological angiogenesis in prostate cancer cell lines. The human prostate cell lines were treated with different concentrations of Simvastatin and ATO alone and combined to find effective doses and IC50 values. In addition, the percentage of apoptotic cells was evaluated by annexin/PI staining, and mRNA expression levels of the apoptotic gene, including OPN isoforms and VEGF, were investigated using real-time PCR. Our data displayed that Simvastatin (12 and 8 μM in PC3 and LNCaP cell lines respectively), ATO (8 and 5 μM in PC3 and LNCaP cell lines respectively), and also their combination (12 μM Simvastatin and 8 μM ATO in PC3, 8 μM Simvastatin and 5 μM ATO in LNCaP cell lines respectively) significantly increased the percentage of apoptotic cells. Also, we showed that the combination therapy by Simvastatin and ATO increased cell apoptosis and inhibited cell proliferation, providing anti-proliferative and anti-angiogenic properties, possibly via downregulation of the expression of VEGF and OPN genes. These results provide new perceptions regarding the anticancer roles of ATO and statins' combination therapy in prostate cancer.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

La notice

Revue
Journal of Cellular and Molecular Medicine
Thématique
Cancer, Lipids, and Metabolism
Domaine
Biochemistry, Genetics and Molecular Biology
Établissements canadiens
Women's College HospitalUniversity of Toronto
Organismes subventionnaires
Mots-clés
LNCaPArsenic trioxideSimvastatinCancer researchApoptosisProstate cancerCell growthAngiogenesisCell cultureAnnexinDownregulation and upregulationChemistryCancerPharmacologyBiologyMedicineInternal medicineBiochemistryGene
Résumé présent dans OpenAlex
oui